Hormone therapy and risk of non-vertebral fracture: Geelong osteoporosis study.
In this population-based study, we evaluated the association between exposure to hormone therapy (HT), bone mineral density (BMD) and the prevalence of non-vertebral fractures. The study was set in a region located in southeastern Australia where complete fracture ascertainment was determined from radiological reports. Current HT use for at least 6 months was ascertained in women with non-vertebral fractures [median age 70.9 years; inter-quartile range (IQR) 66.5-75.9 years] and randomly selected controls (median age 70.8 years; IQR 65.2-75.0 years). Current HT use was documented in 20 of 262 cases and 49 of 364 controls. The odds ratio (OR) for non-vertebral fracture associated with HT use was 0.53 (95% CI 0.31-0.92). HT use was associated with 2.6-7.5% higher BMD at axial and appendicular sites. HT use is associated with a halving of risk for non-vertebral fractures and higher BMD.
Pasco
Julie A
JA
Department of Clinical and Biomedical Sciences: Barwon Health, The University of Melbourne, P.O. Box 281, 3220 Geelong, Australia. juliep@barwonhealth.org.au
Kotowicz
Mark A
MA
Henry
Margaret J
MJ
Sanders
Kerrie M
KM
Seeman
Ego
E
Nicholson
Geoffrey C
GC
D000368:Aged; D015519:Bone Density; D016022:Case-Control Studies; D015914:Estrogen Replacement Therapy; D005260:Female; D050723:Fractures, Bone / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D008875:Middle Aged; D016017:Odds Ratio; D015995:Prevalence; D018570:Risk Assessment